<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-056812</identifier>
<setSpec>1575-0922</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Thyroid cancer, levothyroxine and bone mass. Evidence, experience and three questions</dc:title>
<dc:creator>Reverter Calatayud, Jordi L</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">No disponible</dc:description>
<dc:source>Endocrinol Nutr;54(5): 237-240, mayo  2007.</dc:source>
<dc:identifier>ibc-056812</dc:identifier>
<dc:title xml:lang="es">Cáncer de tiroides, levotiroxina y masa ósea. La evidencia, la experiencia y tres preguntas</dc:title>
<dc:subject>^d29633</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d22696^s22057</dc:subject>
<dc:subject>^d24543^s22021</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d14360^s22020</dc:subject>
<dc:subject>^d1887^s22036</dc:subject>
<dc:type>article</dc:type>
<dc:date>200705</dc:date>
</metadata>
</record>
</ibecs-document>
